Autoimmune haemolytic anaemia

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
2 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 3
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
BTK inhibitor 1 substance
Phase III: 1 Phase II: 1 Phase I (Other): 1

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase III

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    RILZABRUTINIB
    2024-517972-39-00 11 countries 2025 n=58 Orphan
    Recruiting

Phase II

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    RILZABRUTINIB
    2023-509441-13-00 3 countries 2022 n=13
    Ended

Phase I (Other)

1 trial
  • Bioverativ USA Inc. Commercial
    RILIPRUBART
    2023-510210-68-00 3 countries 2021 n=13 Orphan
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Sanofi-Aventis Recherche & Developpement Commercial 2 Phase II, Phase III 1
Bioverativ USA Inc. Commercial 1 Phase I (Other) 0
New trials by year
2021
1
2022
1
2025
1
← All indication landscapes